Kaplan-Meyer plots presenting the <i>CCR5 Δ32/wt</i> genotype based survival prior to cART introduction (a) and on antiretroviral therapy (b).

<p>Kaplan-Meyer plots presenting the <i>CCR5 Δ32/wt</i> genotype based survival prior to cART introduction (a) and on antiretroviral therapy (b).</p

Multivariate model of factors associated with probability of survival in the cohort.

<p>Selection of factors was based on Akaike Information Criterion (AIC) and statistical significance.</p

Hazard ratio changes during observation period.

<p>For calculation multivariate Cox regression adjusted for the six selected factors was used. Upper and lower confidence intervals are indicated as the external limits in the plot. For the values of borderline significance (p = 0.1–0.50) the field is marked in green while values of statistical significance (P<0.05) are marked in blue. a-<i>CCR5</i> genotype, b- gender, c-antiretroviral treatment history, d- CD4 count >500 cells/µl maintained for at least half a year, e-the most recent CD4 count of 100 cells/µl, f- AIDS diagnosis.</p

Multivariate Cox regression model of factors modifying 15 year mortality among HIV infected patients (favorable versus unfavorable parameter).

<p>Dots represent adjusted hazard ratio (HR) for the unfavorable parameters, lines represent confidence intervals for the HR.</p

Causes of non AIDS-related deaths and <i>CCR5 wt/wt</i> vs. <i>CCR5 Δ32/wt</i> genotype.

<p>¹ Hepatic: liver cirrhosis (n = 5), liver insufficiency (n = 3); ² CVD: stroke (n = 1), coronary artery disease (n = 2), pulmonary embolism (n = 1); ³ Non AIDS-related malignancy: Hodgkin lymphoma (n = 1), gastric cancer (n = 1), leukemia (n = 1), testicular cancer (n = 1). Gestosis: death related to pre-eclampsia or eclampsia during pregnancy.</p

Unadjusted hazard ratio and risk of death association basing on selected parameters.

<p>*For AIC calculations equal group size was used, baseline viral load was excluded from this calculation due to poor availability (288 individuals only).</p>1<p>Univariate HR (Hazard Ratio) calculated by unadjusted Cox regression for the same sample sizes as described in the <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0022215#pone-0022215-t001" target="_blank">table 1</a>.</p

Group characteristics by the <i>CCR5</i> genotype.

<p>n/a – non-applicable. Sample sizes vary due to data availability: <i>CCR5</i> genotype, gender, AIDS diagnosis – 507 persons, HCV co-infection status - 464 persons, transmission route and history of antiretroviral treatment – 503 persons, HIV infection stage at diagnosis – 489 persons, baseline viral load (log copies/ml) – 288 persons, baseline lymphocyte CD4 count (cells/µl) – 488 persons, nadir lymphocyte CD4 count (cells/µl) – 494 persons, zenith lymphocyte CD4 count (cells/µl) – 499 persons, time with lymphocyte CD4 count >500 cells/µl – 500 persons, latest lymphocyte CD4 count – 504 persons.</p

Kaplan-Meyer plots for the most significant parameters.

<p>a – <i>CCR5</i> genotype, b- gender, c- HIV infection stage at diagnosis, d – antiretroviral treatment history, e- AIDS diagnosis, f – baseline CD4 count of >50 cells/µl, g – nadir CD4 cells >50 cells/µl, h – zenith CD4 >500 cells/µl, i – the most recent CD4 count >500 cells/µl, j- the most recent CD4 count >500 cells/µl, k- CD4 count >500 cells/µl maintained for at least half a year, l - CD4 count >500 cells/µl maintained for at least one year.</p

Causes of AIDS-related deaths and <i>CCR5 wt/wt</i> vs. <i>CCR5 Δ32/wt</i> genotype.

<p>¹ AIDS-related malignancy: B-cell lymphoma (n = 4), Burkitt lymphoma (n = 1), immunoblastic lymphoma (n = 1), primary CNS lymphoma (n = 4), non-Hodgkin lymphoma - unspecified location (n = 2); ² Fungal infection: pulmonary candidosis (n = 2), generalised cryptococcosis (n = 1); ³ Tuberculosis: pulmonary (n = 4), tuberculotic sepsis (n = 3).</p